MindMed Inc (CAN:MMED / US:MMEDF) has received approval to commence trading on the NASDAQ starting April 27th. Symbol: MNMD.
Psychedelics
Champignon Brands Announces Revocation of Cease Trade Orders
Champignon Brands has had its Cease Trade Order lifted and can resume trading on the CSE effective April 23, 2021 (symbol: SHRM).
Countdown To The atai IPO Begins: atai Files For $100m IPO Financing
With atai Life Sciences filing for a $100 million IPO financing, the countdown to IPO day has begun.
Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and Addiction
Cybin has successfully demonstrated proof of concept for two new drug candidates in internal testing as it moves toward IND status.
Déjà Vu: 2021 Slump In Psychedelic Stocks Mirrors 2020
Low share prices. VERY low trading volumes. The slump in psychedelic stocks in 2021 looks a lot like the slump in 2020.
MINDCURE (CSE: MCUR | OTC: MCURF) Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions
LUCID’s technology platform unites music, AI and research in neuroscience to create personalized digital music therapy managed in real-time by therapists based on patient feedback
Psychedelics are transforming the way we understand depression and its treatment
Mental illness is the 21st century’s leading cause of disability, affecting an estimated billion people across the world.
Cybin Establishes Clinical Advisory Board of Renowned Physicians, Dr. Maurizio Fava, Dr. Lynn Marie Morski and Dr. Anthony Back
Cybin adds several experts in mental health to its Clinical Advisory Board.
Psilocybin’s complicated relationship with creativity revealed in new placebo-controlled neuroimaging study
People under the influence of psilocybin — the active component of magic mushrooms — report having more profound and original thoughts, but tend to score lower on cognitive tests of creative ability, according to new research published in Translational Psychiatry.
Scientists Compared Psilocybin Against Antidepressants For The First Time
WHY AREN’T PEOPLE with depression prescribed magic mushrooms instead of Zoloft or Prozac?
Digital Therapeutics: Optimizing Psychedelics Therapies With Next-Generation IP
Digital therapeutics is the wave of the future in healthcare. The psychedelic drug industry is at the forefront for this new tech.
Novamind Increases Strategic Investment in Bionomics
Novamind increases its strategic investment in Bionomics Limited, in support of its plans for a Phase IIb clinical trial for PTSD.
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
A New England Journal of Medicine study found CMPS's COMP360 psilocybin therapy performed better than the leading antidepressant.
California Bill To Legalize Possession Of Psychedelics Clears Second Senate Committee
A second California Senate committee has approved a bill to legalize possession of a wide range of psychedelics and create a working group to study broader reform.
MINDCURE (CSE: MCUR | OTC: MCURF) Announces The Addition Of Daniel Herrera, A Pharmaceutical Industry Executive With Specific Experience In Medical Psychoactive Segment
Mr. Herrera, Who Will Join The Company As Its Vice President Of Growth And Strategic Partnerships, Has 15+ Years Of Global Life Sciences Experience And Will Help To Drive MINDCURE’s Commercial Focus And Strategic Partnerships